Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arbutus BiopharmaABUS -0.20%53 Cash-to-Debt is 25.55 as of Jun. 2026, which is 61% below its 10-year median of 66.18. GuruFocus rates ABUS with a GF Score™ of 53/100 and a GF Value™ of $48.80 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,393 Biotechnology companies, Arbutus Biopharma ranks better than 80.33% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Arbutus Biopharma's cash to debt ratio for the quarter that ended in Jun. 2026 was 25.55.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Arbutus Biopharmacould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Arbutus Biopharma's Cash-to-Debt or its related term are showing as below:
ABUS'
s Cash-to-Debt Range Over the Past 10 Years
Min: 7.35 Med: 66.18 Max: No Debt
Current: 180.2
During the past 13 years, Arbutus Biopharma's highest Cash to Debt Ratio was No Debt. The lowest was 7.35. And the median was 66.18.
ABUS's Cash-to-Debt is ranked better than 80.33% of 1393
companies
in the Biotechnology industry
Industry Median: 7.03
vs ABUS: 180.20
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Arbutus Biopharma Cash-to-Debt Related Terms
Arbutus Biopharma Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Arbutus Biopharma's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Arbutus Biopharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arbutus Biopharma Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Arbutus Biopharma's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arbutus Biopharma (ABUS) has a Cash-to-Debt of 25.55 as of Jun. 2026. This is 61% below median its historical median of 66.18. Over the past decade, Arbutus Biopharma's Cash-to-Debt has ranged from 7.35 to 10,000.00. According to the industry distribution chart, Arbutus Biopharma ranks #274 out of 1393 companies in the Biotechnology industry, placing it in the top 19.7%.
Is Arbutus Biopharma's Cash-to-Debt too high?
Arbutus Biopharma's current Cash-to-Debt of 25.55 is 61% below median its 10-year median of 66.18. Over the past 10 years, this metric has ranged from a low of 7.35 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 7.03. Arbutus Biopharma's value of 25.55 is 263.4% above this industry median. Based on the distribution chart, Arbutus Biopharma ranks #274 out of 1393 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arbutus Biopharma has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arbutus Biopharma's Cash-to-Debt compare to CADL and WVE?
According to the Biotechnology industry distribution chart, Arbutus Biopharma ranks #274 out of 1393 companies for Cash-to-Debt. This places Arbutus Biopharma in the top 20% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 7.03. Arbutus Biopharma's value of 25.55 is 263.4% above this benchmark. Historically, Arbutus Biopharma's own Cash-to-Debt has ranged from 7.35 to 10,000.00 over the past decade. While the company's 10-year median is 66.18 vs. the industry median of 7.03, Arbutus Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.03, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arbutus Biopharma's current Cash-to-Debt of 25.55 is 263.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arbutus Biopharma's current Cash-to-Debt is 25.55, which is 61% below median its own 10-year median of 66.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arbutus Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Arbutus Biopharma (ABUS) is currently considered Possible Value Trap. The stock's GF Value™ is $48.80, compared to a current price of $5.00 — trading 89.8% below its estimated fair value. The current Cash-to-Debt is 25.55, which is 61% below median its 10-year median of 66.18 and 263.4% above the Biotechnology industry median of 7.03. Arbutus Biopharma's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Arbutus Biopharma (ABUS), the current Cash-to-Debt is 25.55 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arbutus Biopharma (ABUS) Overvalued in 2026?
Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued.
The current stock price of $5.00 is trading 89.8% below its estimated GF Value™ of $48.80.
GuruFocus considers Arbutus Biopharma to be Possible Value Trap.
Key valuation signals for ABUS:
Cash-to-Debt: 25.55 (61% below median its 10-year median of 66.18)
GF Value™: $48.80 vs. price of $5.00 (89.8% below fair value)
Industry Position: 263.4% above the Biotechnology median (#274 of 1393)
No single metric tells the full story. See the ABUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
53GF Score
Get the complete analysis for ABUS
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABUS has been successfully added to your 
